

# Special Issue

## Hodgkin Lymphoma

### Message from the Guest Editor

This Special Issue is dedicated to Hodgkin lymphoma. Almost 190 years after the first description by Thomas Hodgkin, tremendous knowledge about the pathogenesis and treatment of Hodgkin lymphoma has been gained. Still, this tumor remains enigmatic in many aspects. The deregulation of several pathways has been described, but the underlying mechanisms are in many instances not fully understood. Therefore, we here welcome papers that address the molecular biology underlying Hodgkin lymphoma as well as translational studies, with a focus on both tumor and bystander cells, bringing a molecular understanding into clinical context and applied settings. Particularly papers featuring a correlation between pathology and molecular data with respect of Hodgkin lymphoma are of interest.

### Guest Editor

Prof. Dr. Sylvia Hartmann

Senckenberg Institute of Pathology, Goethe University, 60590 Frankfurt am Main, Germany

### Deadline for manuscript submissions

closed (15 September 2022)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/53599](https://mdpi.com/si/53599)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)